Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing monoclonal
antibodies (mAbs) can reduce the risk of hospitalization from coronavirus disease 2019 …

The IgG1 monoclonal antibody (mAb) bamlanivimab (LY-CoV555) prevents viral attachment
and entry into human cells by blocking attachment to the ACE2 receptor. However, whether …

Monoclonal antibodies and antibody cocktails are a promising therapeutic and prophylaxis
for coronavirus disease 2019 (COVID-19). However, ongoing evolution of severe acute …

SARS-CoV-2 antibody therapeutics are being evaluated in clinical and preclinical stages. As
of 11 October 2020, 13 human monoclonal antibodies targeting the SARS-CoV-2 spike …

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) poses a public health
threat for which preventive and therapeutic agents are urgently needed. Neutralizing …

The landscape of SARS-CoV-2 variants dramatically diversified with the simultaneous
appearance of multiple subvariants originating from BA. 2, BA. 4, and BA. 5 Omicron sub …

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants
have become a major concern in the containment of current pandemic. The variants …

The severity of coronavirus disease 2019 (COVID-19) ranges from mild to death, with high
morbidity and mortality rates reported amongst a vulnerable subset of patients termed high …

A fraction of COVID-19 convalescent individuals mount a potent antibody response to SARS-
CoV-2 with cross-reactivity to SARS-CoV-1. To uncover their humoral response in detail, we …

Dear Editor, The spread of the SARS-CoV-2 variants, especially the global variants of
concern (VOCs), could seriously dampen our efforts to tackle the COVID-19 pandemic. The …